glp-1 in europe Uptake by Country: Where Ozempic and Mounjaro are Booming 2026 Europe Glucagon-like Peptide-1 (GLP-1) Agonists

12% of adults had used a GLP-1 prescription drug as of May 2024, and global spending is expected to multiply from $6 billion in 2023 to $105 billion by 2030

Comparison to Existing Treatments: Effectiveness, Safety, And Accessibility Evaluating the effectiveness, safety, and accessibility of new treatment modalities in comparison to traditional therapies is essential in assessing their potential impact

[DOI] [PMC free article] [PubMed] [Google Scholar] 62.Mehta A., Marso S.P., Neeland I.J

Diabetologia (2012) 55:23437

There are no hidden fees, even as your dosage changes over time

Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations